NCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
Clinical Trials
7 trialsNCT04179110 2022-02-22
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Yale University
Phase 2 Withdrawn
NCT05007769 2021-11-05
RAN
Washington University School of Medicine
Phase 2 Withdrawn
NCT02831491 2020-06-09
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Withdrawn
NCT03704077 2020-05-19
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03739801 2020-03-27
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
University of Southern California
Phase 1/2 Withdrawn
NCT03766607 2019-09-19
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Korean South West Oncology Group
Phase 2 Withdrawn